Gouin I, Horellou M H, Conard J, Samama M
Laboratoire central d'hématologie, Hôtel-Dieu, Paris.
Arch Mal Coeur Vaiss. 1990 Mar;83(3):357-61.
The prothrombin time test (PT) is the most common method used for monitoring oral anticoagulant therapy. As a consequence of the variability in responsiveness of different thromboplastins, PT results obtained from patients on oral anticoagulant therapy may not be interchangeable between laboratories and as consequence could produce potential problems for anticoagulant control. The conversion of PT in INR (International Normalized Ratio) has been introduced recently to standardise the PT used for anticoagulant control. 127 determinations of prothrombin time and INR with 2 different thromboplastin reagents (Thromboplastin C Dade and Owren reagent) have been performed in 73 patients. This study confirm the usefulness of the INR (INR discrepancy in 10% of the cases) despite the imperfections concerning the choice of the control plasma and the need of a precise measurement of the ISI, International Sensitivity index. In parallel, changes in therapeutic ranges for anticoagulant therapy occurred, based on results of the international literature: less intense anticoagulant treatment (INR 2-3) is effective against recurrent venous thromboembolism with reduced bleeding. Different therapeutic ranges must be recommended for oral anticoagulant therapy according to the indication of the treatment.
凝血酶原时间试验(PT)是监测口服抗凝治疗最常用的方法。由于不同凝血活酶的反应性存在差异,接受口服抗凝治疗患者的PT结果在不同实验室之间可能无法互换,因此可能会给抗凝控制带来潜在问题。最近引入了将PT转换为国际标准化比值(INR)的方法,以规范用于抗凝控制的PT。对73例患者使用2种不同的凝血活酶试剂(达德凝血活酶C和欧文试剂)进行了127次凝血酶原时间和INR测定。本研究证实了INR的有效性(10%的病例中INR存在差异),尽管在对照血浆的选择以及国际敏感指数(ISI)精确测量方面存在不足。同时,根据国际文献结果,抗凝治疗的治疗范围发生了变化:强度较低的抗凝治疗(INR 2 - 3)对复发性静脉血栓栓塞有效,且出血减少。根据治疗指征,口服抗凝治疗必须推荐不同的治疗范围。